ライフサイエンスコーパス: P2Y12 receptor

1 in was potentiated by ADP acting through the P2Y12 receptor.

2 y active, and its activity is potentiated by P2Y12 receptors.

3 ATP release, and microglial response through P2Y12 receptors.

4 d an autocrine ADP-mediated response through P2Y12 receptors.

5 addition to that derived from antagonism of P2Y12 receptors.

6 CysLT1R and CysLT2R but not in mice lacking P2Y12 receptors.

7 d in the initiation of platelet aggregation, P2Y12 receptor activation appears to account for the bul

8 process outgrowth to damaged tissue requires P2Y12 receptor activation but is unaffected by blocking

9 Furthermore, we show that P2Y12 receptor activation is not required for protease-a

10 of a local thrombus, dual inhibition of the P2Y12 receptor and calcium mobilization result in a comp

11 is dependent on both the G(alpha)(i)-coupled P2Y12 receptor and the G(alpha)(q)-coupled P2Y1 receptor

12 mole inhibit platelet function by inhibiting P2Y12 receptors and platelet phosphodiesterase, respecti

13 supporting pleiotropic effects coupled with P2Y12 receptor antagonism.

14 s a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inh

15 ubstituents on the ribose and base conferred P2Y12 receptor antagonist properties to these molecules

16 The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the inci

17 The P2Y12 receptor antagonist ticagrelor has been shown to b

18 escribed an additional mode of action of the P2Y12 receptor antagonist ticagrelor.

19 On the other hand, apyrase, the P2Y12 receptor antagonist, AR-C67085, and indomethacin o

20 However, pretreatment of platelets with P2Y12 receptor antagonist, AR-C69331MX did not interfere

21 on of platelets with aspirin, but not with a P2Y12 receptor antagonist, caused a marked reduction in

22 d by either the integrin inhibitor RGDS or a P2Y12 receptor antagonist, indicating a requirement for

23 Physicians considering prescription of P2Y12-receptor antagonist for long-term (>1 year) protec

24 heral arterial disease, or following a brief P2Y12-receptor antagonist interruption, whereas clopidog

25 Platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with

26 lar patients who smoke benefit from platelet P2Y12 receptor antagonists more than their nonsmoking pe

27 ntagonists), cyclopentyltriazolopyrimidines (P2Y12 receptor antagonists), anti-von Willebrand factor

28 al study, consisting of the thienopyridines (P2Y12 receptor antagonists), cyclopentyltriazolopyrimidi

29 morphine and its potential interactions with P2Y12 receptor antagonists, as well as on the central is

30 P2Y12 receptor antagonists, concurrently administered wi

31 As head-to-head comparative trials between P2Y12-receptor antagonists are lacking, selection of a s

32 r and inside-out signaling from the P2Y1 and P2Y12 receptors are necessary for phospholipase A(2) act

33 Platelet P2Y12 receptors are the targets of very widely used anti

34 namides, which are potent antagonists of the P2Y12 receptor, are presented.

35 The powerful antithrombotic effects of P2Y12 receptor blockers may, in part, be mediated by pro

36 P did not require Gi signaling or functional P2Y12 receptors but was mediated through activation of a

37 Both P2Y1 and P2Y12 receptors can also undergo PMA-stimulated internal

38 In platelets from a P2Y12 receptor-defective patient, alpha-thrombin, SFLLRN

39 rful synergism is explained by blockade of a P2Y12 receptor-dependent, NO/cGMP-insensitive phosphatid

40 epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) f

41 thus reduces surveillance, whereas blocking P2Y12 receptors does not affect membrane potential, rami

42 Here we show that blockade of platelet P2Y12 receptors dramatically enhances the antiplatelet p

43 P2Y12 receptor expression by LAD2 cells is required for

44 P2Y12 receptor expression permits LTE4-induced activatio

45 26 directly and indirectly affects ADAM9 and P2Y12 receptor expression.

46 ently identified functional effector for the P2Y12 receptor, in the regulation of ADP-induced TXA2 ge

47 treatment platelet reactivity and incomplete P2Y12 receptor inhibition are risk factors for SAT.

48 stenting and treatment strategies to improve P2Y12 receptor inhibition in patients with high post-tre

49 phoprotein phosphorylation levels to measure P2Y12 receptor inhibition were determined (n = 20) and c

50 pidogrel metabolism, potentially attenuating P2Y12 receptor inhibition.

51 with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated.

52 studies, mice were treated with the platelet P2Y12 receptor inhibitor clopidogrel or placebo.

53 sk in major bleeding by combining aspirin, a P2Y12 receptor inhibitor, and an anticoagulant.

54 me (ACS) patients are not pre-treated with a P2Y12 receptor inhibitor, and percutaneous coronary inte

55 d to treat excessive bleeding in patients on P2Y12 receptor inhibitors (RI).

56 P2Y12 receptor inhibitors clinically in use such as clop

57 after discharge for beta-blockers, platelet P2Y12 receptor inhibitors, statins, and angiotensin-conv

58 ess and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.

59 Blocking P2Y12 receptor is a clinically well-validated strategy f

60 Thus, the P2Y12 receptor is required for proinflammatory actions o

61 uated by PKC inhibitors, whereas that of the P2Y12 receptor is unaffected.

62 osine diphosphate (ADP)-reactive purinergic (P2Y12) receptor is required for LTE4-mediated pulmonary

63 Because clopidogrel antagonizes the platelet P2Y12 receptor, it is widely prescribed for patients wit

64 Ligand docking on P2Y1 and P2Y12 receptor models was guided by mutagenesis results,

65 In platelets from mice lacking the P2Y12 receptor, neither alpha-thrombin nor AYPGKF caused

66 ntial signalling and cell activation through P2Y12 receptor or receptor heterodimers but no specific

67 The human P2Y12 receptor (P2Y12-R) is a member of the G protein co

68 P2Y12 receptor (P2Y12-R) signaling is mediated through G

69 Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of

70 ed BSM contraction is blocked by a selective P2Y12 receptor (P2Y12R) antagonist, PSB 0739 (25 muM), b

71 Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP)

72 The P2Y12 receptor (P2Y12R), one of eight members of the P2Y

73 th tests measuring the adenosine diphosphate-P2Y12 receptor pathway, without significant variations i

74 Platelet P2Y12 receptors play a central role in the regulation of

75 elated factors (higher on-treatment platelet P2Y12 receptor reactivity and premature thienopyridine d

76 ene adenosine 5'-triphosphate (AR-C67085), a P2Y12 receptor-selective antagonist, and adenosine-2'-ph

77 inhibited in the presence of AR-C69931MX, a P2Y12 receptor-selective antagonist, or GF 109203X, a pr

78 or that abolishes secretion, or AR-C66096, a P2Y12 receptor-selective antagonist; alpha-thrombin-indu

79 Cloning of the P2Y12 receptor should facilitate the development of bett

80 PMA reduced subsequent ADP-induced P2Y1 and P2Y12 receptor signaling.

81 ators is ADP, which, acting through platelet P2Y12 receptors, strongly amplifies aggregation.

82 in undergoes synergy with ADP acting via the P2Y12 receptor whereas there is no synergy via the P2Y1